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Abstract
Penile traction therapy has traditionally been implemented to increase penile length but has recently
been investigated for reducing the curvature associated with Peyronie’s disease. The results of a few
initial investigations have been conflicting, and further research is needed to confirm the true benefit
of such therapy and its potential role in treating Peyronie’s disease as both a monotherapy and in
combination with other therapeutic options.
Introduction and context
Peyronie’s disease (PD) is a connective tissue disorder
involving the tunica albuginea layer of the penis. The
fibrotic process that occursmay result in the formation of
plaque, one of the classic findings on physical examina-
tion of the patient. Men afflicted by this disorder may
present with pain, deformity (such as penile curvature or
penile shortening) and/or erectile dysfunction (ED).
While surgical therapy has been the standard definitive
treatment for penile curvature associated with PD, less
invasive options have been sought. Aside from the
common risks associated with surgical procedures,
corrective surgery for the penile curvature associated
with PD can result in further penile shortening and
worsening penile rigidity with erection [1-4]. Medical
options are attractive due to their potential to avoid
invasive procedures of the penis, to affect all aspects of
the disease, and to intervene before the disease has
stabilized and is no longer reversible. However, no single
medical treatment has been definitively proven to offer a
significant benefit in a large placebo-controlled trial
[5,6]. In addition, no medical or surgical therapy offers
the benefit of increased penile length to men with PD,
a common sequela of the disease and one that can cause
significant emotional distress.
While the search for an effective non-surgical therapy for
PD has continued, interest in the use of external
mechanical force has arisen. The use of a vacuum
erection device (VED) has been recommended as an
option for treatment of the shortening, curvature, and
ED associated with PD. It has also been investigated as an
adjunctive therapy to be used in combination with
surgical treatment of PD [7]. To date, no large multi-
center controlled trial has been performed to validate the
use of a VED in these situations.
While the use of traction therapy in PD may be a
relatively new concept, it has a long history of use in
other areas of medicine. In 1969, Ilizarov and Soibeman
[8] described ‘distraction osteogenesis’ as a technique to
stimulate bone remodeling. Subsequently, the use of
traction and tissue expansion therapy has spread to other
areas, including orthodontics and plastic/reconstructive
surgery [9]. From these initial experiences, the concept of
using traction therapy to lengthen the penis was felt to be
a logical consideration. In 2001, Scroppo and colleagues
[10] reported the results of a small study that investi-
gated the use of penile traction to treat PD curvature.
Eight men with PD and no complaints of ED were
instructed to use a penile traction device for at least 4
hours per day for a total treatment period of 3-6 months.
The authors reported a statistically significant decrease in
mean erect curvature of 14° (from 34 to 20°). However,
this study involved a very small cohort of patients with
no control group.
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[11] reported on the use of a traction device to treat
penile shortening that had occurred after PD surgery.
A total of 40 men participated in this study, with
12 undergoing a grafting procedure while the remaining
28 underwent plication only. One-half of the patients
were treated with penile traction and the other half
served as the control group. The penile extender was
first instituted once the surgical incision had healed
(approximately 2-3 weeks) for 8-12 hours daily for a
total treatment period of at least 4 months. For both
groups, penile shortening after surgery ranged from
0.5-4.0 cm. Those patients in the treatment group
experienced a length increase ranging from 1-3 cm and
this increase was proportional to the number of hours
per month that the patient was wearing the extender. The
authors also studied the potential impact of the device
on the quality of life of their study groups and identified
significant differences in several parameters for the
patients using the device versus those in the control
group.
Recent advances
Based on these initial positive studies, further investiga-
tion into the use of penile traction as a non-surgical
alternative in the treatme n to fP Dd e f o r m i t yw a s
encouraged. In 2008, Levine and colleagues [12]
reported the results of a study of 11 men with PD who
underwent treatment with a penile traction device. All
participants were evaluated with pre-treatment measure-
ment of stretched penile length from pubis to corona,
and a dynamic color duplex ultrasound was performed
with measurement of curvature and girth at maximal
erection. Of the 11 men who entered the study, one
subject dropped out due to inability to comply with
the treatment protocol. Patients were instructed to wear
the device for a minimum of 2 hours per day but
were encouraged to increase the duration of use to a
maximum of 8 hours per day. Treatment was continued
for a total of 6 months. Every 2 weeks, the extender
rods were lengthened by 0.5 cm, and repeat length
measurements were recorded every month during an
office visit.
Of the 10 men who completed the study, all reported
subjective improvements in length and curvature of
0.5-2.5 cm and 10-40°, respectively. Objectively, mean
penile stretched length increased from 0.5-2.0 cm and
curvature had been reduced by 10-45° (mean of 22°).
There were no patient-described changes regarding
penile sensation, worsening erectile function, or skin
injury. Overall, patients reported high satisfaction rates
and improvements in International Index of Erectile
Function (IIEF) scores.
This year, Gontero and colleagues [13] published the
results of a study of 19 men who underwent treatment
with a penile traction device for PD-associated penile
curvature. Of the men participating, all had pre-
treatment curvature of less than 50°, disease lasting a
minimum of 12 months, and no penile pain when
flaccid. In contrast to the Levine study, measurements of
curvature were determined by photography taken by the
investigators after a pharmacologically induced erection
in the office or, for patients who refused, by auto-
photography at home. Patients were required to wear the
device for a minimum of 5 hours daily, up to a
maximum of 9 hours. Patients were evaluated at months
1, 3, and 6. After finishing treatment at month 6, they
were evaluated again at 12 months (washout period of
6months).Atotaloffourpatientsweredroppedfromthe
final analysis due to lack of compliance with the protocol
or were lost to follow-up. For the remaining 15 patients
available for analysis, median daily use of the device was
5.5 hours. Penile curvature decreased from a mean of
31° to 27°. Although this was not statistically significant,
there was a significant improvement in mean flaccid
and stretched penile length measurements of 1.3 and
0.83 cm, respectively. No further changes in curvature or
length were noted after the washout period. There was
only a marginal improvement in IIEF score, which was
also not statistically significant.
There are several potential explanations for the large
discrepancies in the findings between the Levine and
Gontero studies. The selection criteria for each study
were quite different. For example, the Gontero study
required all patients to have the stable form of the
disease, which possibly meant that this patient group
had disease symptoms that were less amenable to
therapy. The Gontero study also limited their study
group to patients with curvature of less than 50°, which
may have reduced the potential impact of traction
therapy. In addition, it is difficult to compare changes
in IIEF scores as the treatment group from both studies
differed in their baseline scores. Treatment protocol and
methods of evaluation were not kept constant across
both studies.
Implications for clinical practice
While the value of traction forces in treating various
medical conditions has been established, its role in the
treatment of the deformities associated with PD has yet
to be defined. Initial studies have indicated a role in
promoting recovery of penile length lost as a result of the
disease. More recent investigations have validated this,
although a large controlled trial has yet to be performed.
Of the few studies that have been done, contrasting
evidence exists as to how beneficial a traction device may
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moderate improvement may be anticipated, a lack of
uniformity in the evaluation of patients across these
studies causes the results to be difficult to interpret. Until
uniform methods of evaluating PD patients are agreed
upon across these studies, a definitive answer will be
difficult to reach [14].
As the search for effective non-surgical therapies for PD
continues, some have proposed a role for ‘combination
therapy’, with traction therapy being a potential compo-
nent. In fact, Abern and Levine [15] reported on such a
protocol in a study of 71 men. In this non-controlled
study, a greater improvement in penile curvature was
seen in those patients who elected to undergo verapamil
injection along with penile traction therapy as opposed
to those who underwent injection therapy alone. Again,
no definitive recommendations for changes in clinical
practice can be made from these findings, but similar
studies are forthcoming. Until these investigations
involve larger cohorts in a controlled study, it will
continue to prove difficult for definitive recommenda-
tions to be made.
The investigation of the use of traction therapy in treating
men with PD is still in its infancy. Although no large
multi-center controlled trials have been published to
date, the initial reports are promising. Whether traction
therapy will prove beneficial as a monotherapy or in
combination with other therapies remains to be seen.
At this point, penile traction appears to be a safe and
potentially effective option for men wishing to minimize
loss of length after corrective surgery for PD. It may also
be a reasonable alternative for men who are not
candidates for surgery or refuse surgery, and who are
wishing to seek modest improvements in recovery of
length and penile curvature.
Abbreviations
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